Drug Trial Radar · NCT03675893
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Dec 24, 2018
Primary completion
Aug 1, 2028
Study completion Aug 1, 2031
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eli Lilly and Company; Celcuity Inc
- First posted
- Sep 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Gedatolisib (also known as PF-05212384)
Conditions
- Endometrial Cancer
Interventions
LetrozoleDrug
Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
AbemaciclibDrug
Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
LY3023414Drug
LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
MetforminDrug
Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
GedatolisibDrug
Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival RateTime frame: 6 months
- Objective Tumor Response RateTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.